Exosome Characterisation: The Quality Control Panel Explained
1. Nanoparticle Tracking Analysis (NTA)
What It Measures
NTA measures particle concentration (particles per mL) and size distribution in a liquid sample. The instrument tracks Brownian motion of individual particles under laser illumination, calculating hydrodynamic diameter from diffusion coefficients using the Stokes-Einstein equation.
Why It Matters
NTA establishes the baseline concentration of a product and confirms that particles fall within the expected exosome size range of 30–150 nm. Without this measurement, there is no quantitative basis for dosing consistency between batches.
What to Look For on a COA
Concentration: Reported as particles/mL with a defined coefficient of variation. A credible NTA result includes the instrument model, camera settings, and number of capture frames. Batch-to-batch variation should be documented.
Size distribution: The modal peak should fall between 80–150 nm for HMSC-derived exosomes. A significant population above 200 nm may indicate the presence of microvesicles or aggregates. A bimodal distribution warrants further investigation.
Limitations
NTA cannot distinguish exosomes from other particles of similar size - protein aggregates, lipid droplets, and cellular debris all register as particles. NTA concentration alone is not a measure of exosome purity or biological potency. It must be interpreted alongside TEM and surface marker data.
A high particle count without morphological and molecular confirmation is a number without meaning. Counting particles is not characterising exosomes.
2. Transmission Electron Microscopy (TEM)
What It Measures
TEM provides direct visual confirmation of vesicle morphology at nanometre resolution. Samples are typically prepared by negative staining with uranyl acetate or phosphotungstic acid and imaged at magnifications of 50,000–200,000×. The resulting images reveal the characteristic cup-shaped or round morphology of intact exosomal vesicles.
Why It Matters
TEM is the only analytical method that directly confirms the physical presence of intact vesicles. It distinguishes true exosomes from membrane fragments, protein aggregates, and other nanoparticulate contaminants that NTA would count as particles. Without TEM, there is no visual evidence that the product contains vesicles at all.
What to Look For on a COA
TEM images should show a population of vesicles with intact lipid bilayer membranes, characteristic round or cup-shaped morphology, and size consistent with the NTA distribution. The images should be taken from the batch being released, not from a reference batch or stock image. Scale bars must be present and legible.
Red flags include: images showing predominantly fragmented membranes, excessive aggregation, particles with non-vesicular morphology, or the absence of TEM data entirely.
3. ELISA Tetraspanin Panel (CD9, CD63, CD81)
What It Measures
Enzyme-linked immunosorbent assay (ELISA) quantifies the presence of specific surface proteins on exosomal membranes. The three canonical exosome markers - CD9, CD63, and CD81 - are tetraspanin proteins enriched on the surface of exosomal vesicles. Their presence confirms exosome identity at the molecular level.
Why It Matters
The International Society for Extracellular Vesicles (ISEV) MISEV guidelines identify tetraspanin expression as a minimum requirement for exosome characterisation. A product testing negative for all three markers cannot be confidently identified as exosomal in nature. Positive tetraspanin expression, combined with TEM morphological confirmation, establishes a two-dimensional identity verification.
What to Look For on a COA
Results should report quantitative expression levels for CD9, CD63, and CD81 against defined positive thresholds. Ideally, the assay should also test for negative markers - proteins that should be absent from purified exosome preparations, such as calnexin (an endoplasmic reticulum marker) or GM130 (a Golgi marker). Their absence confirms effective purification from cellular contaminants.
4. RNA Sequencing - miRNA Cargo Profiling
What It Measures
RNA sequencing identifies and quantifies the microRNA (miRNA) cargo encapsulated within exosomal vesicles. miRNAs are small non-coding RNA molecules (18–25 nucleotides) that regulate gene expression in target cells. The miRNA cargo profile is the primary functional payload of HMSC exosomes and the molecular basis for their observed biological effects.
Why It Matters
Without cargo profiling, there is no evidence that the product contains biologically active molecules. A vial can contain intact vesicles with correct surface markers and still carry a depleted or altered cargo profile due to suboptimal culture conditions, high passage number, or degradation during processing.
Research indicates that specific miRNAs drive specific biological responses. miR-21 and miR-146a are associated with anti-inflammatory signalling. miR-29 family members are associated with extracellular matrix remodelling. Let-7 family miRNAs play roles in cell proliferation regulation. The cargo profile determines functional potential.
What to Look For on a COA
A credible cargo profile reports the top expressed miRNAs with normalised expression values and consistency metrics across batches. Batch-to-batch cargo reproducibility is a key quality indicator - high variability suggests inconsistent manufacturing conditions.
Cargo Profiling vs. Particle Counting - The Critical Distinction
- NTA measures quantity - how many particles are in the vial
- TEM confirms structure - whether those particles are intact vesicles
- ELISA confirms identity - whether those vesicles are exosomes
- RNA-seq confirms function - whether those exosomes carry biologically relevant cargo
5. USP <71> Sterility Testing
What It Measures
USP <71> is the United States Pharmacopeia compendial method for sterility testing of pharmaceutical products. The test inoculates product samples into two growth media - fluid thioglycollate medium (FTM) for anaerobic and aerobic bacteria, and soybean-casein digest medium (SCDM) for fungi and aerobic bacteria - and incubates for a minimum of 14 days.
Why It Matters
Any product intended for injection or topical application to patients must demonstrate sterility to a pharmaceutical standard. Basic sterility testing (shorter incubation periods, fewer media types) does not meet the rigour of USP <71>. For biologics derived from human cell culture, where the manufacturing environment includes biological growth media, the sterility assurance level is non-negotiable.
What to Look For on a COA
The COA should explicitly reference USP <71> as the test method, report the incubation duration (14 days minimum), and state a clear pass/fail result for each medium. The testing laboratory should be identified and ideally accredited.
6. LAL Endotoxin Assay
What It Measures
The Limulus Amebocyte Lysate (LAL) assay detects and quantifies bacterial endotoxins (lipopolysaccharides from gram-negative bacteria). Endotoxins are potent inflammatory agents that can persist even after sterilisation procedures. The LAL reagent, derived from horseshoe crab blood cells, forms a gel or produces a colour change in the presence of endotoxins, enabling quantitative measurement in endotoxin units per millilitre (EU/mL).
Why It Matters
Endotoxin contamination is one of the most common causes of adverse inflammatory reactions following biological product administration. A product can pass sterility testing (no viable organisms) and still contain dangerously high endotoxin levels from organisms present earlier in the production process. Endotoxin testing is therefore a separate and complementary safety assurance.
What to Look For on a COA
The result should be reported as EU/mL with a defined acceptance limit. Best practice for exosome biologics is <0.1 EU/mL post-reconstitution. The test method (kinetic turbidimetric, kinetic chromogenic, or gel-clot) and sensitivity of the assay should be documented. Any result reported simply as "pass" without quantitative values warrants further enquiry.
7. Viral Screening Panel
What It Measures
A comprehensive viral screening panel tests for the presence of transmissible viral pathogens in the donor source material and final product. A 14-pathogen panel typically covers: HIV-1/2, Hepatitis B (HBsAg, anti-HBc), Hepatitis C, HTLV-I/II, CMV, EBV, Parvovirus B19, Syphilis (Treponema pallidum), and additional pathogens as required by regulatory frameworks.
Why It Matters
Exosome biologics are derived from human tissue. The risk of viral transmission from donor to recipient via biological products is well established in transfusion medicine and must be addressed with equivalent rigour for cell-derived biologics. Comprehensive viral screening at the donor level, combined with testing at intermediate and final product stages, creates a layered safety assurance.
What to Look For on a COA
The panel should enumerate all pathogens tested, report individual results for each, and identify the testing methodology (PCR, serology, or both). The testing should trace back to the original donor source. Batch-level viral screening of the final product provides an additional layer of safety assurance beyond donor-level testing alone.
8. Protein Quantification (BCA Assay)
What It Measures
The bicinchoninic acid (BCA) assay quantifies total protein concentration in a sample. In the context of exosome biologics, protein quantification provides a complementary measure of product concentration alongside NTA particle count. It also enables calculation of the protein-to-particle ratio, a useful purity metric.
Why It Matters
A disproportionately high protein-to-particle ratio may indicate contamination with free proteins from the culture medium or cell lysis products. A low ratio relative to particle count suggests a cleaner preparation with less protein contamination. When tracked across batches, this ratio provides a simple but informative quality consistency metric.
What to Look For on a COA
Total protein should be reported in µg/mL alongside the NTA particle count. The protein-to-particle ratio can then be calculated and compared across batches. Significant variation may indicate inconsistencies in the isolation or purification process.
Summary: The Complete Characterisation Panel
| Test | What It Confirms | Key Metric |
|---|---|---|
| NTA | Particle concentration and size | Particles/mL, modal diameter |
| TEM | Vesicle morphology and integrity | Intact bilayer structure |
| ELISA | Exosome identity (surface markers) | CD9/CD63/CD81 expression |
| RNA-seq | Biological cargo and potency | miRNA profile, batch consistency |
| USP <71> | Sterility | 14-day pass/fail |
| LAL | Endotoxin safety | <0.1 EU/mL |
| Viral Screen | Pathogen safety | 14-pathogen panel negative |
| BCA | Protein concentration and purity | Protein-to-particle ratio |
Reading a Certificate of Analysis
When reviewing a COA from any exosome supplier, apply these criteria systematically:
- Completeness: Does the COA include all eight tests above? Missing tests indicate incomplete characterisation. A supplier reporting only NTA and sterility is providing a fraction of the required quality data.
- Batch specificity: Is the COA linked to a specific batch number and production date? A generic COA that does not reference the specific batch being shipped is not meaningful quality documentation.
- Quantitative results: Are results reported with numerical values, or only as pass/fail? Quantitative data enables comparison and trend analysis. Pass/fail alone provides no information about where in the acceptable range the result falls.
- Testing laboratory: Is the testing laboratory identified? Are they accredited? Third-party testing by an accredited laboratory provides stronger quality assurance than in-house testing alone.
- Release criteria: Are acceptance limits defined for each test? A result without a specification is an observation, not a quality control measurement.
A COA is a quality commitment, not a marketing document. Every number on it should be auditable, batch-specific, and measured against a defined acceptance criterion.
Conclusion
Comprehensive characterisation is the foundation of exosome product quality. Each of the eight analytical methods described above addresses a distinct dimension - quantity, structure, identity, function, sterility, endotoxin safety, viral safety, and purity. No single test is sufficient in isolation. Together, they form a multi-dimensional quality profile that enables practitioners and researchers to make informed procurement decisions.
The absence of any test from a supplier's characterisation panel is not a minor omission. It is a gap in the evidence that the product is what it claims to be, that it is safe to administer, and that it contains the biological cargo required for the intended application.
For a practical guide to evaluating suppliers against these standards, see Selecting an HMSC Exosome Supplier. For questions about BEXO's quality documentation, contact our team.